New Medical and Injectable Treatments for LUTS/BPH - Anticholinergics, PDE-5, and Botox

Steven J. Weissbart, Karl Coutinho, Dean S. Elterman, Bilal Chughtai

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Although alpha-blockers, 5-alpha-reductase inhibitors and prostatectomy are clearly efficacious treatment options for men with LUTS/BPH, these therapies are less than perfect. This has led to the investigation of new treatment options for men with LUTS/BPH. Three of these new treatment options include anticholinergics, phosphodiesterase-5-inhibitors (PDE5I), and botulinum toxin A (BoNT-A). Of these, anticholinergics and PDE5I have demonstrated a clear efficacy in appropriately selected patients. On the other hand, despite initial promising data, recent studies have not supported a clear efficacy with intraprostatic BoNT-A. The literature on anticholinergics, PDE5I, and BoNT-A is reviewed. Areas for future research within the field are then presented along with guidelines for prescribing these therapies.

Original languageEnglish
Pages (from-to)114-121
Number of pages8
JournalCurrent Bladder Dysfunction Reports
Issue number2
StatePublished - Jun 2014


  • 5-alpha-reductase inhibitors
  • Adrenergic alpha-antagonists
  • BPH
  • Benign prostatic hyperplasia
  • Cholinergic antagonists
  • Combined modality therapy
  • LUTS
  • Lower urinary tract symptoms
  • OnabotulinumtoxinA
  • Phosphodiesterase inhibitors
  • Prostatectomy
  • Prostatic diseases
  • Urinary retention
  • Urinary tract
  • Voiding dysfunction


Dive into the research topics of 'New Medical and Injectable Treatments for LUTS/BPH - Anticholinergics, PDE-5, and Botox'. Together they form a unique fingerprint.

Cite this